个人信息
Personal Information
联系方式
Contact Information
个人简介
Personal Profile
刘宣雨(Dr. Xuanyu Liu),河北宣化人。2008年本科毕业于中国农业大学,2011年获得中国科学院研究生院(现中科院大学)理学硕士学位,2015年获得瑞士苏黎世联邦理工大学(Swiss Federal Institute of Technology in Zurich)理学博士学位(导师:Alex Widmer教授)。具备生物信息学、细胞生物学和分子生化等知识背景。先后在基因测序企业和中国医学科学院阜外医院从事研发和博士后研究工作(合作导师:周洲教授)。目前担任中国医学科学院阜外医院副研究员、研究生导师,心血管疾病国家重点实验室Co-PI。
研究兴趣是通过对高维度、多模态数据(以单细胞和空间组学数据为代表)的整合挖掘结合体外细胞功能学实验、在体动物模型来解析心血管疾病的病理发生机制和发现新的治疗靶点。
近年来聚焦于遗传性心血管疾病(例如遗传性的先天性心脏病、主动脉病和心肌病)的病理机制解析,开展了一系列临床基础研究及临床前研究。以第一或通讯作者在Circulation Research、Cell Discovery、Advanced Science、Cell Reports、ATVB、EMBO Reports等国际著名期刊发表多篇研究论文,被发表在Nature期刊在内的领域内重要论文多次引述,研究成果得到国际同行的专门评论文章肯定。主持包括国家自然科学基金、国家高水平医院临床研究基金在内的多项基金项目。担任国内外学术期刊编委及审稿人。
课题组依托于心血管疾病国家重点实验室、心血管疾病分子诊断北京市重点实验室和阜外医院实验诊断中心(周洲主任团队),实验条件一流,经费充足,科研氛围自由活跃。本课题组致力于将研究生培养成同时具备生物医学大数据挖掘能力(生物信息学)和生物学实验能力,同时具有独立科学思维和国际视野的优秀科研人员。本课题组队专业背景要求相对宽泛,生物学、医学、检验、生物信息学等专业皆可考虑。欢迎有识之士积极报考!
Dr. Xuanyu Liu was born in Xuanhua, Hebei. In 2008, he graduated with a bachelor's degree from China Agricultural University, and in 2011, he obtained a master's degree in science from the Graduate University of the Chinese Academy of Sciences (now University of the Chinese Academy of Sciences). In 2015, he received his Ph.D. in science from the Swiss Federal Institute of Technology in Zurich, under the supervision of Professor Alex Widmer.
Dr. Liu has a knowledge background in bioinformatics, cell biology, and molecular biochemistry. He has worked at sequencing companies and the Fuwai Hospital, Chinese Academy of Medical Sciences, engaging in R&D and postdoctoral research, respectively, under the collaborative supervision of Professor Zhou Zhou.
Currently, Dr. Liu serves as an Associate Research Fellow and graduate supervisor at the Fuwai Hospital, Chinese Academy of Medical Sciences, and is a Co-PI at the State Key Laboratory of Cardiovascular Disease.
Dr. Liu's research interests focus on elucidating the pathological mechanisms of cardiovascular diseases and discovering new therapeutic targets. He integrates the mining of high dimensional, multimodal data with in vitro cellular functional experiments and in vivo animal models.
In recent years, the focus of Dr. Liu's research has been on elucidating the pathological mechanisms of hereditary cardiovascular diseases, such as hereditary congenital heart diseases, aortic diseases, and cardiomyopathies. As the first author or corresponding author, he has published research papers in internationally renowned journals, including Circulation Research, Cell Discovery, Advanced Science, Cell Reports, ATVB, and EMBO Reports. These publications have been cited by important papers in the field, including those published in Nature, and his research achievements have been recognized by specialized review articles from the international peers.
Dr. Liu has hosted multiple research projects, including grants from the National Natural Science Foundation of China and the National High Level Hospital Clinical Research Fund. He also serves as an editorial board member and reviewer for academic journals.
The research group led by Dr. Liu is supported by the State Key Laboratory of Cardiovascular Disease, the Beijing Key Laboratory of Molecular Diagnostics for Cardiovascular Diseases, and the Experimental Diagnostic Center of Fuwai Hospital (led by Director Zhou Zhou). The group has first class experimental conditions, ample funding, and an active research atmosphere. The group is dedicated to cultivating graduate students into outstanding researchers who possess both biomedical big data mining and biological experimental skills, as well as independent scientific thinking and an international perspective. The group welcomes talented individuals with degrees in biology, medicine, laboratory science, bioinformatics, and other related fields to apply.
上传附件
支持扩展名:.rar .zip .doc .docx .pdf .jpg .png .jpeg上传附件
支持扩展名:.rar .zip .doc .docx .pdf .jpg .png .jpeg上传附件
支持扩展名:.rar .zip .doc .docx .pdf .jpg .png .jpegRepresentative publications (#: 第一作者 the first author; *: 通讯作者 correspondence author)
● Xuanyu Liu, Meng Yuan, Danni Zhao, Qingyi Zeng, Wenke Li, Tianjiao Li, Qi Li, Yue Zhuo, Mingyao Luo, Pengfei Chen, Liqing Wang, Wei Feng, Zhou Z. Single Nucleus Transcriptomic Atlas of Human Pericoronary Epicardial Adipose Tissue in Normal and Pathological Conditions. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024;ATVBAHA.124.320923 (中科院一区,JCR Q1, IF: 8.7)
● Xuanyu Liu (#), Qingyi Zeng (#), Hang Yang, Wenke Li, Qianlong Chen, Kunlun Yin, Zihang Pan, Kai Wang (*), Mingyao Luo (*), Chang Shu (*), Zhou Zhou (*). Single nucleus Multiomic Analyses Identifies Gene Regulatory Dynamics of Phenotypic Modulation in Human Aneurysmal Aortic Root. Advanced Science, 2024;11:2400444(中科院一区,JCR Q1, IF: 15.1)
● Xuanyu Liu (#), Huayan Shen (#), Jinxing Yu, Fengming Luo, Qi Li, Xin Yuan, Yang Sun (*), Zhou Zhou (*). Resolving the heterogeneous tumour microenvironment in cardiac myxoma through single cell and spatial transcriptomics. Clinical And Translational Medicine, 2024;14:e1581(中科院一区,JCR Q1, IF: 10.6)
● Xuanyu Liu (#), Kunlun Yin (#), Liang Chen (#), Wen Chen, Wenke Li, Taojun Zhang, Yang Sun, Meng Yuan, Hongyue Wang, Yunhu Song, Shuiyun Wang (*), Shengshou Hu (*), Zhou Zhou (*). Lineage-specific regulatory changes in hypertrophic cardiomyopathy unraveled by single-nucleus RNA-seq and spatial transcriptomics. Cell Discovery, 2023, 9:6(中科院一区,JCR Q1, IF: 33.5)
● Xuanyu Liu (#), Wen Chen (#), Guoyan Zhu (#), Hang Yang, Wenke Li, Mingyao Luo, Chang Shu (*), Zhou Zhou (*). Single-cell RNA-seq identifies an Il1rn+/Trem1+ macrophage subpopulationas a cellular target for mitigating the progression of thoracic aortic aneurysmand dissection. Cell Discovery, 2022, 8:11(中科院一区,JCR Q1, IF: 38.09)
● Xuanyu Liu (#), Meng Yuan (#), Qinqin Xiang, Zhujun Li, Fen Xu, Wen Chen, Jie Chen, Jiuzuo Huang, Nanze Yu, Zhou Zhou (*), Xiao Long (*). Single-cell RNA sequencing of subcutaneous adipose tissues identifies therapeutic targets for cancer-associated lymphedema. Cell Discovery, 2022, 8:58(中科院一区,JCR Q1, IF: 38.09)
● Xuanyu Liu (#), Wen Chen (#), Qingyi Zeng (#), Zhujun Li, Tian Meng, Jie Chen, Nanze Yu, Zhou Zhou (*), Xiao Long (*). Single-cell RNA-seq reveals lineage-specific regulatory changes of fibroblastsand vascular endothelial cells in keloid. Journal of Investigative Dermatology, 2022, 142:124-135(中科院一区,JCR Q1, IF: 7.59)
● Wen Chen, Xuanyu Liu (*), Wenke Li, Ziyi Zeng, James R. Priest, Zhou Zhou (*). Single-cell transcriptomic landscape of cardiac neural crest cell derivatives during development. EMBO Reports, 2021, 22:1-18(中科院一区,JCR Q1, IF: 9.071)
● Xuanyu Liu (#), Wen Chen (#), Wenke Li, James R. Priest, Yuanyuan Fu, Kunjing Pang, Baihui Ma, Bianmei Han, Xuewen Liu, Shengshou Hu (*), Zhou Zhou (*). Exome-based case-control analysis highlights the pathogenic role of ciliarygenes in transposition of the great arteries. Circulation Research, 2020, 126:811-821(中科院一区,JCR Q1, IF: 17.367)
● Xuanyu Liu (#), Wen Chen, Wenke Li, Yan Li, Bin Zhou, James R.Priest, Jikui Wang (*), Zhou Zhou (*). Single-cell RNA-seq of the developing cardiac outflow tract reveals convergent development of the vascular smooth muscle cells. Cell Reports, 2019, 28:1346-1361.e4(中科院一区,JCR Q1, IF: 8.109)
① 单细胞水平解析心脏流出道发育和畸形(先心病)发生的机制 首次绘制了发育过程中的心脏流出道的单细胞转录图谱,提出大动脉基部平滑肌细胞的汇聚发育新模式,并系统地揭示出纤毛基因突变和人类散发大动脉转位先心病(一种严重的流出道畸形)的关联(代表作:Cell Reports,2019,28:1346-1361.e4;EMBO Reports,2021,22:e52389;Circulation Research,2020,126:811-821)。该系列研究从发育生物学的角度为探讨流出道畸形发生的细胞分子机制奠定了基础,进而为大动脉转位先心病的产前分子诊断和临床治疗管理提供了重要指导。研究策略上,将传统的谱系追踪动物模型与前沿的单细胞组学技术巧妙结合,具有创新性。美国爱荷华大学心血管医学部的Barry London教授于Circulation Research同期发表专门评论文章(London B.,Circulation Research,2022,126:822-823),称该研究为纤毛基因与大动脉转位的关联提供了证据支持,是领域内的“step forward”(向前一步)。该系列研究先后被哈佛医学院遗传学系著名专家Christine E. Seidman教授及英国帝国理工学院Antonio M. A. Miranda教授发表的重要综述引用并给予了正面评价(Morton et al.,Nature Reviews Cardiology,2022,19:26-42; Miranda et al. Nature Reviews Cardiology,2023,20:289-308)。此外,该系列研究还被发表在包括Nature期刊在内的领域内重要研究论文引述(如Litviňuková et al.,Nature,2020,588:466-472)。 ② 单细胞和空间维度上解析遗传性胸主动脉疾病—胸主动脉瘤/夹层的病理发生机制 首次通过分析BAPN诱导的小鼠胸主动脉瘤和夹层进展过程中的单细胞转录组,发现TREM1+巨噬细胞亚群可作为延缓胸主动脉瘤/夹层进展的细胞干预靶点(Cell Discovery,2022,8:11);该研究从抗炎的角度为胸主动脉瘤/夹层的靶向药物治疗提供了新的靶点及相应药物,具有潜在的临床应用价值,受到临床医学专家和基础研究同行的高度评价。该成果被美国密西根大学心外科专家Dogukan Mizrak教授新近发表的胸主动脉单细胞组学重要综述引述(Dogukan et al.,Arteriosclerosis Thrombosis and Vascular Biology,2022,42:919-930)。首次构建人类主动脉根部组织在健康和疾病(马凡综合征相关主动脉根部瘤)状态下的单细胞核转录组与染色质可及性图谱,以及空间转录图谱,发现FOXN3是维持主动脉平滑肌细胞收缩性的关键调控因子,可作为潜在的治疗新靶点(Advanced Science, 2024)。 ③ 单细胞和空间维度上解析肥厚型流出道梗阻性心肌病及其它组织纤维化相关疾病的病理机制 |
首次发现AEBP1是调控心脏成纤维细胞活化的转录抑制因子;首次发现皮下脂肪组织纤维化相关的PRG4+成纤维细胞亚群,并发现其潜在干预靶点CLEC3B;首次解析了瘢痕皮肤组织纤维化相关的细胞亚群,并发现其潜在干预靶点TWIST1及相应药物(代表作:Cell Discovery,2023,9:6;Cell Discovery,2022,8:58;Journal of Investigative Dermatology,2022,142:124-135;Scientific Data,2019,6:190031;Scientific Data,2019,6:90)。该系列研究从抑制心脏纤维化、改善病理性心脏重塑的角度为肥厚型流出道梗阻性心肌病的治疗提供了新的靶点和思路,发现的新靶点和药物具有潜在临床应用价值,获得临床、基础和医药产业界专家的广泛好评。该系列研究被发表在包括Nature期刊在内的领域内重要研究论文引述(如Chaffin et al.,Nature,2022,608:174-180)。
文件上传中...